"Overcoming Resistance to Immune Checkpoint Blockade with Precision Cancer Immunotherapy."

Roberta Zappasodi, PhD.
Assistant Professor of Hematology in Medicine, Division of Hematology & Medical Oncology, Parker Bridge Scholar, Parker Institute for Cancer Immunotherapy, Weill Cornell Medicine.

Objectives:

- discuss steps which led to identify a new non-conventional immunosuppressive CD4+ T-cell subset as an activity biomarker of immune checkpoint blockade therapy and the mechanisms underlying activity of another form of immunotherapy with GITR agonist antibodies as well as the rationale supporting its combination with PD-1 blockage.

THANK YOU TO OUR SPONSORS: